

## **PainScript Platform Improves Patient Outcomes**

*Observation Trial Demonstrates 5% to 28% improvement in key clinical measures  
Data suggests that telehealth technology can improve patient outcomes via increased treatment plan compliance and medication adherence*

**Washington, D.C./ACCESSWIRE – September 6, 2022** — PainScript™, a company focused on providing physicians with improved treatment protocols for chronic pain patients, announced today that *TheResearchPost* has completed a peer-review assessment and accepted for publication a 55,000 patient records observational trial, titled “*Mobile Health Technology and Pain Management.*” Publication is scheduled for September 6, 2022.

“Chronic pain imposes a significant burden on individuals and society, and adherence to treatment protocols and medication regimens is a key contributor to patient safety and treatment effectiveness,” said Dan Cohen, CEO of PainScript. “The ability to more closely monitor patients to ensure adherence with care plans and compliance with medication regimes should lead to better outcomes. This trial is suggestive of those positive patient outcomes.”

“The PainScript technology provides support for pharmacologic and nonpharmacologic treatment and offers the potential for early detection of adverse events,” said Lynn Webster, MD, Chief Medical Officer of PainScript and one of the trial authors. “In addition to this benefit, and as the controlled substance act (CSA) requires that an opioid be prescribed for a medical purpose, the PainScript approach documents when an opioid is prescribed for a medical purpose and it also confirms assessments of the ongoing effects of the medication which can show regulatory bodies that the physician is complying with the CSA,” Webster added.

The Observation Trial published the following conclusions:

- Preliminary observational data suggests that mHealth telehealth technology can improve patient care through increased treatment plan compliance and medication adherence.
- The mHealth (PainScript) platform appears to improve patient/provider interaction in the gap that occurs between office visits.
- Limited patient/provider interactions can result in insufficient documentation to support treatment decisions and provide an affirmative litigation defense.
- Improving physician-patient communication and patient monitoring may reduce the risk of opioid misuse and addiction and provide clinicians with information that can help differentiate substance use disorders from tolerance and physical dependence.
- The mHealth platform may also provide a physician or provider’s practice with a means to be compensated by payors for the time and expertise of providing daily contact with patients.
- The documentation in the mHealth platform appears compliant with “Ruan vs. U.S.” and may serve as an affirmative litigation defense due to enhanced communication and affirmative documentation.

### **RESULTS**

Through June 30, 2022, patients provided more than 55,000 individual daily clinical responses to their physicians in diverse locations across the United States. Through 12 weeks, patients achieved a 99.8% adherence to their prescribed medication regimen – including taking/not taking prescription and non-prescription medications as directed. There was a statistically significant linear trend across a 12-week time period for all outcomes except cravings. Cravings had a downward trend over time, but the pattern was more cyclic than linear. Other measures, such as pain levels, feelings of anxiety or depression, fatigue, and cravings are based on standard 0 – 10 scales.

- Pain- Improvement from baseline 5.5%
- Fatigue- Improvement from baseline 13%
- Depression- Improvement from baseline 19%
- Anxiety- Improvement from baseline 28%
- Cravings- Improvement from baseline 28%

With the PainScript technology, patients receive a daily reminder to self-report symptoms. The check-in typically consists of three clinically validated questions and the mHealth platform provides automated triages of the patient's responses based on expected normative results, with thresholds that can be customized per patient. A designated, qualified healthcare provider evaluates the responses, escalating the results to the appropriate level of provider for decision-making. Medication adherence is self-assessed by patients reporting metrics such as whether they take all meds as prescribed.

Authors: Dr. Lynn Webster, MD, Dr. Jeff Gudin, MD, and Dr. Charles Argoff, MD, and Mr. Scott Cashon, Chief Technology Officer at PainScript.

[Link to publication.](#)

###

### **About PainScript**

PainScript, a subsidiary of Optimus Healthcare Services, Inc. (**OTC: OHCS**), is a telehealth medical technology company built on the clinically proven Med-eXpert system that connects physicians with their chronic pain and substance use disorder patients daily by tracking medication and care plan adherence through an easy-to-use, clinically-validated app. PainScript provides physicians with detailed patient insight, a HIPAA-compliant clinical dashboard, and tools for medication monitoring. The platform provides medically necessary support to patients who are suffering from chronic pain and substance use disorder by using real-time data and daily digital care. PainScript helps physicians, patients, and practices by bolstering patient experience and offering practices an affirmative litigation defense through clinical documentation and daily tracking of patient symptoms with the implementation of machine learning technologies.

### **About Optimus**

Optimus Healthcare Services is focused on creating a network of innovative healthcare companies that advance clinical research, disease management and improve physician/patient interactions. A prime focus will include acquiring controlling interests in a variety of healthcare-related businesses.

### **Caution Concerning Forward Looking Statements:**

This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “will,”

“expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not a guarantee of future actions or performance. These forward-looking statements are based on information currently available to PainScript and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning OHCS business are described in Periodic and Current Reports filed with the OTCIQ. Optimus is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

**Contact:**

Dan Cohen  
Chief Executive Officer, PainScript  
[dlc@painscript.com](mailto:dlc@painscript.com)  
202-329-1825